Table 1.
Most commonly mutated non-BRCA1/2 tumor tissue genes in patients with tBRCAmut (evaluable ITT population).
| Talazoparib n/N (%) | Chemotherapy n/N (%) | Combined n/N (%) | ||
|---|---|---|---|---|
| Mutations | ||||
| TP53 | ||||
| tBRCA1mut only | 76/90 (84.4) | 39/45 (86.7) | 115/135 (85.2) | |
| tBRCA2mut only | 23/102 (22.5) | 16/55 (29.1) | 39/157 (24.8) | |
| tBRCA1mut and tBRCA2mut | 0/1 (0.0) | 0/3 (0.0) | 0/4 (0.0) | |
| tBRCA1mut or tBRCA2mut | 99/193 (51.3) | 55/103 (53.4) | 154/296 (52.0) | |
| PIK3CA | ||||
| tBRCA1mut only | 6/90 (6.7) | 1/45 (2.2) | 7/135 (5.2) | |
| tBRCA2mut only | 16/102 (15.7) | 9/55 (16.4) | 25/157 (15.9) | |
| tBRCA1mut and tBRCA2mut | 0/1 (0.0) | 0/3 (0.0) | 0/4 (0.0) | |
| tBRCA1mut or tBRCA2mut | 22/193 (11.4) | 10/103 (9.7) | 32/296 (10.8) | |
| Known/likely pathogenic CNAs | ||||
| MYC | ||||
| tBRCA1mut | 16/90 (17.8) | 12/45 (26.7) | 28/135 (20.7) | |
| tBRCA2mut | 21/102 (20.6) | 11/55 (20.0) | 32/157 (20.4) | |
| tBRCA1mut and tBRCA2mut | 0/1 (0.0) | 2/3 (66.7) | 2/4 (50.0) | |
| tBRCA1mut or tBRCA2mut | 37/193 (19.2) | 25/103 (24.3) | 62/296 (20.9) | |
| RAD21 | ||||
| tBRCA1mut | 10/90 (11.1) | 13/45 (28.9) | 23/135 (17.0) | |
| tBRCA2mut | 23/102 (22.5) | 16/55 (29.1) | 39/157 (24.8) | |
| tBRCA1mut and tBRCA2mut | 0/1 (0.0) | 1/3 (33.3) | 1/4 (25.0) | |
| tBRCA1mut or tBRCA2mut | 33/193 (17.1) | 30/103 (29.1) | 63/296 (21.3) | |
Note: tBRCA-mutated ITT population includes all patients with tumor samples suitable for the genomic evaluation and analyzed using FoundationOne CDx who have BRCA mutations (variants with known or likely pathogenic impact, excluding CNAs). Genes shown exhibit mutations (known/likely pathogenic variant, CNAs excluded) or known/likely pathogenic CNAs in ≥10% of patients in combined arms.